The contract is funded by the Defense Threat Reduction Agency (DTRA).
According to the terms of the company’s contract with the Science and Technology Corporation, anti-ricin antibodies will be delivered to an agency of the US Army, the Edgewood Chemical and Biological Center (ECBC).
AnaptysBio president and chief executive officer Hamza Suria said, "Our platform’s features have permitted AnaptysBio to rapidly develop a differentiated internal product pipeline against emerging targets of interest to pharma."
The company has recently published the development of multiple full-length antibodies with unprecedented thermostability properties leveraging a proprietary antibody scaffold in conjunction with SHM-XEL.
The antibodies dependency on cold chain is reduced due to the extended stability at room temperature.